Federal and Regulatory Outreach
AMRPA’s Comment Letter on the CMS Proposed IRF Review Choice Demonstration
February 17, 2021
Regulatory Review Choice Demonstration
AMRPA Second Round Comment Letter to NQF on IRF Measure Under Consideration
January 19, 2021
COVID-19 Quality Regulatory
AMRPA Comment Letter to NQF on IRF Measure Under Consideration
January 6, 2021
COVID-19 Quality Regulatory
AMRPA Responds to MedPAC December 2020 Session on IRF Payment Adequacy and Access
December 29, 2020
Medicare Advantage MedPAC Regulatory
AMRPA Submits Comments on HHS RFI on COVID-19 Regulatory Changes
December 28, 2020
Burden Reduction COVID-19 Prior Authorization Regulatory Telehealth
AMRPA Submits Policy Priorities & Recommendations to Biden-Harris Transition Team
December 18, 2020
COVID-19 IMPACT Act Legislative Medicare Advantage Price Transparency Prior Authorization Telehealth
AMRPA Comments to CMS/RTI Regarding Unified PAC PPS Prototype Work
December 17, 2020
IMPACT Act Regulatory Unified PAC Payment
AMRPA Statement on Proposed CMS IRF Choice Review Demonstration
December 15, 2020
Regulatory Review Choice Demonstration
AMRPA & NALTH Send Joint Letter to CMS on Medicare Advantage Prior Authorization
December 9, 2020
Medicare Advantage Prior Authorization Regulatory
AMRPA Submits Comment to CMS on CY 2022 Medicare Advantage and Part D Advance Notice Parts I and II
November 30, 2020
Medicare Advantage Prior Authorization Regulatory
AMRPA Submits Comments to CMS on Medicare Care Compare Site
November 12, 2020
COVID-19 Price Transparency
AMRPA & NALTH Send Joint Response to CMS on Medicare Advantage Prior Authorization Issues during the Public Health Emergency